Breast Cancer Patients Forego Post-Surgery Treatment Due to Mistrust, Study Suggests

Excerpt:

“Nearly one-third of women with breast cancer went against their doctor’s advice and chose not to begin or complete the recommended adjuvant anti-cancer therapy to kill residual tumor cells following surgery, according to a study led by a Johns Hopkins Bloomberg School of Public Health researcher.

“A survey that included 2,754 breast cancer patients in Florida and Pennsylvania during a two-year period found that this ‘treatment discordance’ – not following a doctor’s recommended treatment plan in its entirety – was more likely among patients who reported a general distrust of medical institutions and insurers. The patients’ trust or distrust of their own doctors did not seem to be a factor.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


Cost of Cancer Drugs Strongly Affects Treatment Adherence

A study of over 1,500 cancer patients showed that drug costs have a significant effect on whether patients stick to their treatment plan. The study’s subjects had been prescribed imatinib (Gleevec), a treatment for chronic myeloid leukemia, a type of blood cancer. Patients with higher co-payments were 42% more likely to skip doses and 70% percent more likely to stop taking Gleevec entirely. Missing only 15% of prescribed Gleevec doses significantly raises the chance of the cancer developing drug resistance and relapsing. The study also found drastic differences in out-of-pocket treatment costs, with co-payments ranging from nothing to $4,792 for a 30-day supply of Gleevec. The average co-payment amount more than doubled over the 9-year course of the study.


Cost of Cancer Drugs Strongly Affects Treatment Adherence

A study of over 1,500 cancer patients showed that drug costs have a significant effect on whether patients stick to their treatment plan. The study’s subjects had been prescribed imatinib (Gleevec), a treatment for chronic myeloid leukemia, a type of blood cancer. Patients with higher co-payments were 42% more likely to skip doses and 70% percent more likely to stop taking Gleevec entirely. Missing only 15% of prescribed Gleevec doses significantly raises the chance of the cancer developing drug resistance and relapsing. The study also found drastic differences in out-of-pocket treatment costs, with co-payments ranging from nothing to $4,792 for a 30-day supply of Gleevec. The average co-payment amount more than doubled over the 9-year course of the study.


Cost of Cancer Drugs Strongly Affects Treatment Adherence

A study of over 1,500 cancer patients showed that drug costs have a significant effect on whether patients stick to their treatment plan. The study’s subjects had been prescribed imatinib (Gleevec), a treatment for chronic myeloid leukemia, a type of blood cancer. Patients with higher co-payments were 42% more likely to skip doses and 70% percent more likely to stop taking Gleevec entirely. Missing only 15% of prescribed Gleevec doses significantly raises the chance of the cancer developing drug resistance and relapsing. The study also found drastic differences in out-of-pocket treatment costs, with co-payments ranging from nothing to $4,792 for a 30-day supply of Gleevec. The average co-payment amount more than doubled over the 9-year course of the study.